drugset / Trial / NCT01612988
Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL
NaSingle-groupOpen-labelTreatment
Summary
ICLL01 The BOMP trial: Phase II study of salvage treatment with Bendamustine, Ofatumumab and MethylPrednisolone (BOMP) in relapsed B-cell chronic lymphocytic leukemia (B-CLL). A study of the GOELAMS / GCFLLC-MW intergroup
Timeline
- Start
- 2012-07
- Primary completion
- 2015-12
- Completion
- 2018-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 70 mg | Intravenous |
| Subject | Methylprednisolone | Other / unclassified | 1000 mg/m2 | Intravenous |
| Subject | Ofatumumab | Monoclonal antibody | 1000 mg | Intravenous |